

## LIST OF FIGURES

| <b>Fig. No.</b> | <b>Figure Title</b>   | <b>Page No.</b> |
|-----------------|---|-----------------|
| Fig. 1.1        | Creation and stabilization of nanoparticles, from the perspective of surface energetics.  | 07              |
| Fig. 1.2        | Schematic illustration of Ostwald ripening.   | 09              |
| Fig. 1.3        | Schematic representation of the parameters of Noyes-Whitney equation.   | 11              |
| Fig. 1.4        | Schematic diagram of “Top Down” and “Bottom Up” methods for preparation of Nanoparticles (Nano Engineering in Pharmaceuticals). | 13              |
| Fig. 1.5        | Various approaches for production of Nanoparticle/Nanosuspension.   | 14              |
| Fig. 1.6        | Molecular dimensions, shape and chemical structure, of $\alpha$ -, $\beta$ - and $\gamma$ -cyclodextrins.                       | 28              |
| Fig. 1.7        | Conventional models of drug-cyclodextrin complex formation and equilibrium.   | 33              |
| Fig. 1.8        | Phase solubility relationships.   | 35              |
| Fig. 1.9        | Molecular structure of Diacerein (DAR).   | 45              |
| Fig. 1.10       | Molecular structure of Febuxostat (FBX).  | 47              |
| Fig. 3.1        | (A) Overlay spectra and (B) Calibration curve of DAR in methanol.   | 71              |
| Fig. 3.2        | (A) Overlay spectra and (B) Calibration curve of DAR in distilled water.  | 71              |
| Fig. 3.3        | (A) Overlay spectra and (B) Calibration curve of DAR in phosphate Buffer pH 6.8.  | 71              |
| Fig. 3.4        | (A) Overlay spectra and (B) Calibration curve of DAR in acetate buffer pH 4.5.  | 72              |
| Fig. 3.5        | (A) Overlay spectra and (B) Calibration curve of DAR in acetate buffer pH 4.5.  | 72              |
| Fig. 3.6        | (A) Overlay chromatogram and (B) Calibration curve of DAR in mobile phase.  | 78              |
| Fig. 3.7        | (A) Overlay chromatogram and (B) Calibration curve of DAR in HBSS buffer.   | 85              |
| Fig. 3.8        | (A) Overlay chromatogram and (B) Calibration curve of rhein in plasma.  | 92              |
| Fig. 3.9        | (A) Overlay spectra and (B) Calibration curve of FBX in Methanol.   | 98              |
| Fig. 3.10       | (A) Overlay spectra and (B) Calibration curve of FBX in Distilled water.  | 98              |

|           |  |     |
|-----------|--|-----|
| Fig. 3.11 | (A) Overlay spectra and (B) Calibration curve of FBX in Phosphate Buffer pH 6.8.   | 99  |
| Fig. 3.12 | (A) Overlay spectra and (B) Calibration curve of FBX in Acetate Buffer pH 4.5.   | 99  |
| Fig. 3.13 | (A) Overlay spectra and (B) Calibration curve of FBX in 0.1N HCl.  | 99  |
| Fig. 3.14 | (A) Overlay chromatogram and (B) Calibration curve of FBX in mobile phase.   | 105 |
| Fig. 3.15 | (A) Overlay chromatogram and (B) Calibration curve of FBX in HBSS buffer.  | 110 |
| Fig. 3.16 | (A) Overlay chromatogram and (B) Calibration curve of FBX in plasma.   | 116 |
| Fig. 4.1  | Reduction of yellow Tetrazole into purple Formazan.  | 136 |
| Fig. 4.2  | Diagram of a Caco-2 monolayer grown on a permeable filter.   | 137 |
| Fig. 4.3  | Graphical representation of stabilizer's effect on mean particle size of DAR-NS.   | 144 |
| Fig. 4.4  | Contour plots showing effect of (a) $X_1$ vs $X_2$ (at 0 level of $X_3$ ), (b) $X_1$ vs $X_3$ (at 0 level of $X_2$ ) and (c) $X_2$ vs $X_3$ (at 0 level of $X_1$ ) on PS of DAR-NS.          | 153 |
| Fig. 4.5  | Contour plots showing effect of (a) $X_1$ vs $X_2$ (at 0 level of $X_3$ ), (b) $X_1$ vs $X_3$ (at 0 level of $X_2$ ) and (c) $X_2$ vs $X_3$ (at 0 level of $X_1$ ) on SS of DAR-NS.          | 154 |
| Fig. 4.6  | Response surface plots showing effect of (a) $X_1$ vs $X_2$ (at 0 level of $X_3$ ), (b) $X_1$ vs $X_3$ (at 0 level of $X_2$ ) and (c) $X_2$ vs $X_3$ (at 0 level of $X_1$ ) on PS of DAR-NS. | 155 |
| Fig. 4.7  | Response surface plots showing effect of (a) $X_1$ vs $X_2$ (at 0 level of $X_3$ ), (b) $X_1$ vs $X_3$ (at 0 level of $X_2$ ) and (c) $X_2$ vs $X_3$ (at 0 level of $X_1$ ) on SS of DAR-NS. | 156 |
| Fig. 4.8  | Particle size distribution of DAR-NS by Malvern Zetasizer.   | 160 |
| Fig. 4.9  | Particle size distribution of Plain DAR by Malvern Mastersizer   | 160 |
| Fig. 4.10 | Zeta potential report of DAR-NS by Malvern Zetasizer.  | 161 |
| Fig. 4.11 | DSC thermograms of (A) Plain DAR, (B) Poloxamer 407, (C) Trehalose, (D) Physical Mixture for DAR-NS (PM) and (E) Freeze dried DAR-NS.  | 162 |
| Fig. 4.12 | XRD spectra of (A) Plain DAR, (B) Physical Mixture for DAR-NS (PM) and (C) Freeze dried DAR-NS.  | 163 |
| Fig. 4.13 | SEM image of plain DAR.  | 164 |
| Fig. 4.14 | SEM image of DAR-NS.   | 164 |
| Fig. 4.15 | TEM image of DAR-NS  | 165 |

|           |   |     |
|-----------|---|-----|
| Fig. 4.16 | Graphical representation of % Cumulative drug release versus sampling time of DAR-P, DAR-M and freeze dried DAR-NS in phosphate buffer pH-6.8 (PB), acetate buffer pH-4.5 (AB), 0.1N HCl and water.                                     | 167 |
| Fig. 4.17 | In vitro cytotoxicity studies of DAR-P and DAR-NS in Caco2 cell lines at 4 hours.   | 170 |
| Fig. 4.18 | In vitro cytotoxicity studies of DAR-P and DAR-NS in Caco2 cell lines at 24 hours.  | 171 |
| Fig. 4.19 | In vitro cytotoxicity studies of DAR-P and DAR-NS in Caco2 cell lines at 48 hours.  | 171 |
| Fig. 4.20 | Graphical representation of rhein plasma profile for DAR-P, DAR-M and DAR-NS in Albino rabbits following oral administration.   | 174 |
| Fig. 4.21 | Phase solubility studies of DAR with CDs in distilled water.  | 191 |
| Fig. 4.22 | Phase solubility studies of DAR with CDs in Phosphate Buffer pH6.8.   | 192 |
| Fig. 4.23 | Phase solubility studies of DAR with CDs in 0.1N HCl pH-1.2.  | 192 |
| Fig. 4.24 | IR spectrums of (A) Plain DAR, (B) HP- $\beta$ -CD, (C) Physical Mixture for DAR:HP- $\beta$ -CD::(1:2)M, (D) Kneaded Mixture for DAR:HP- $\beta$ -CD::(1:2)M and (E) Freeze dried inclusion complex of DAR:HP- $\beta$ -CD::(1:2)M.    | 196 |
| Fig. 4.25 | DSC thermograms of (A) Plain DAR, (B) HP- $\beta$ -CD, (C) Physical Mixture for DAR:HP- $\beta$ -CD::(1:2)M, (D) Kneaded Mixture for DAR:HP- $\beta$ -CD::(1:2)M and (E) Freeze dried inclusion complex of DAR:HP- $\beta$ -CD::(1:2)M. | 198 |
| Fig. 4.26 | XRD patterns of (A) Plain DAR, (B) HP- $\beta$ -CD, (C) Physical Mixture for DAR:HP- $\beta$ -CD::(1:2)M, (D) Kneaded Mixture for DAR:HP- $\beta$ -CD::(1:2)M and (E) Freeze dried inclusion complex of DAR:HP- $\beta$ -CD::(1:2)M.    | 199 |
| Fig. 4.27 | Graphical representation of % Cumulative drug release versus sampling time of DAR-P, DAR-M and Freeze dried DAR-IC in phosphate buffer pH-6.8 (PB), acetate buffer pH-4.5 (AB), 0.1N HCl and water.                                     | 201 |
| Fig. 4.28 | In vitro cytotoxicity studies of DAR-P and DAR-IC in Caco2 cell lines at 4 hours.   | 204 |
| Fig. 4.29 | In vitro cytotoxicity studies of DAR-P and DAR-IC in Caco2 cell lines at 24 hours.  | 205 |
| Fig. 4.30 | In vitro cytotoxicity studies of DAR-P and DAR-IC in Caco2 cell lines at 48 hours.  | 205 |

|           |  |     |
|-----------|--|-----|
| Fig. 4.31 | Graphical representation of rhein plasma profile for DAR-P, DAR-M and DAR-IC in Albino rabbits following oral administration.  | 209 |
| Fig. 5.1  | Graphical representation of stabilizer's effect on mean particle size of FBX-NS.   | 230 |
| Fig. 5.2  | Contour plots showing effect of (a) $X_1$ vs $X_2$ (at 0 level of $X_3$ ), (b) $X_1$ vs $X_3$ (at 0 level of $X_2$ ) and (c) $X_2$ vs $X_3$ (at 0 level of $X_1$ ) on PS of FBX-NS.                | 238 |
| Fig. 5.3  | Contour plots showing effect of (a) $X_1$ vs $X_2$ (at 0 level of $X_3$ ), (b) $X_1$ vs $X_3$ (at 0 level of $X_2$ ) and (c) $X_2$ vs $X_3$ (at 0 level of $X_1$ ) on SS of FBX-NS.                | 239 |
| Fig. 5.4  | Response surface plots showing effect of (a) $X_1$ vs $X_2$ (at 0 level of $X_3$ ), (b) $X_1$ vs $X_3$ (at 0 level of $X_2$ ) and (c) $X_2$ vs $X_3$ (at 0 level of $X_1$ ) on PS of FBX-NS.       | 240 |
| Fig. 5.5  | Response surface plots showing effect of (a) $X_1$ vs $X_2$ (at 0 level of $X_3$ ), (b) $X_1$ vs $X_3$ (at 0 level of $X_2$ ) and (c) $X_2$ vs $X_3$ (at 0 level of $X_1$ ) on SS of FBX-NS.       | 241 |
| Fig. 5.6  | Particle size distribution of FBX-NS by Malvern Zetasizer.   | 245 |
| Fig. 5.7  | Particle size distribution of Plain FBX by Malvern Mastersizer.  | 245 |
| Fig. 5.8  | Zeta potential report of FBX-NS by Malvern Zetasizer.  | 245 |
| Fig. 5.9  | DSC thermograms of (A) Plain FBX, (B) Poloxamer 188, (C) Trehalose, (D) Physical Mixture for FBX-NS (PM) and (E) Freeze dried FBX-NS.  | 247 |
| Fig. 5.10 | XRD spectra of (A) Plain FBX, (B) Physical Mixture for FBX-NS (PM) and (C) Freeze dried FBX-NS.  | 248 |
| Fig. 5.11 | SEM image of plain FBX.  | 249 |
| Fig. 5.12 | SEM image of FBX-NS.   | 249 |
| Fig. 5.13 | TEM image of FBX-NS.   | 250 |
| Fig. 5.14 | Graphical representation of % Cumulative drug release versus sampling time of FBX-P FBX-M and freeze dried FBX-NS in phosphate buffer pH-6.8 (PB), acetate buffer pH-4.5 (AB), 0.1N HCl and water. | 252 |
| Fig. 5.15 | In vitro cytotoxicity studies of FBX-P and FBX-NS in Caco2 cell lines at 4 hours.  | 256 |
| Fig. 5.16 | In vitro cytotoxicity studies of FBX-P and FBX-NS in Caco2 cell lines at 24 hours.   | 256 |
| Fig. 5.17 | In vitro cytotoxicity studies of FBX-P and FBX-NS in Caco2 cell lines at 48 hours.   | 256 |
| Fig. 5.18 | Graphical representation of FBX plasma profile for FBX-P, FBX-M and FBX-NS in Albino rabbits following oral administration.  | 261 |
| Fig. 5.19 | Phase solubility studies of FBX with CDs in distilled water.   | 275 |

|           |  |     |
|-----------|--|-----|
| Fig. 5.20 | Phase solubility studies of FBX with CDs in Phosphate Buffer pH6.8.  | 275 |
| Fig. 5.21 | Phase solubility studies of FBX with CDs in 0.1N HCl pH-1.2.   | 276 |
| Fig. 5.22 | IR spectrums of (A) Plain FBX, (B) HP- $\beta$ -CD , (C) Physical Mixture for FBX: HP- $\beta$ -CD::(1:1)M, (D) Kneaded Mixture for FBX: HP- $\beta$ -CD::(1:1)M and (E) Freeze dried inclusion complex of FBX: HP- $\beta$ -CD::(1:1)M. | 280 |
| Fig. 5.23 | DSC thermograms of (A) Plain FBX, (B) HP- $\beta$ -CD, (C) Physical Mixture for FBX:HP- $\beta$ -CD::(1:1)M, (D) Kneaded Mixture for FBX:HP- $\beta$ -CD::(1:1)M and (E) Freeze dried inclusion complex of FBX:HP- $\beta$ -CD::(1:1)M.  | 282 |
| Fig. 5.24 | XRD patterns of (A) Plain FBX, (B) HP- $\beta$ -CD , (C) Physical Mixture for FBX: HP- $\beta$ -CD::(1:1)M, (D) Kneaded Mixture for FBX: HP- $\beta$ -CD::(1:1)M and (E) Freeze dried inclusion complex of FBX: HP- $\beta$ -CD::(1:1)M. | 283 |
| Fig. 5.25 | Graphical representation of % Cumulative drug release versus sampling time of FBX-P, FBX-M and Freeze dried FBX-IC in phosphate buffer pH-6.8 (PB), acetate buffer pH-4.5 (AB), 0.1N HCl and water.                                      | 285 |
| Fig. 5.26 | In vitro cytotoxicity studies of FBX-P and FBX-IC in Caco2 cell lines at 4 hours.  | 288 |
| Fig. 5.27 | In vitro cytotoxicity studies of FBX-P and FBX-IC in Caco2 cell lines at 24 hours.   | 289 |
| Fig. 5.28 | In vitro cytotoxicity studies of FBX-P and FBX-IC in Caco2 cell lines at 48 hours.   | 289 |
| Fig. 5.29 | Graphical representation of FBX plasma profile for FBX-P, FBX-M and FBX-IC in Albino rabbits following oral administration.  | 293 |